Amgen Inc.

NASDAQ Global Select
Back to all articles
Slightly Bullish +15

Amgen Inc. $AMGN Shares Sold by Bank of New York Mellon Corp

AI-generated analysis

📉 Bank of New York Mellon Corp reduced its Amgen stake by 2.9% in Q1, selling 113,573 shares while retaining a $1.33 billion position.

📈 Smaller institutional investors including Anfield Capital and Dogwood Wealth Management significantly increased their holdings in the fourth quarter.

📊 Analyst consensus price target stands at $356.62 with an average rating of 'Hold' based on data from MarketBeat.

💰 Amgen reported Q1 EPS of $5.15, beating estimates by $0.38 and generating revenue of $8.62 billion.

📈 Revenue grew 5.8% year-over-year to exceed analyst expectations of $8.58 billion for the quarter.

💹 The company achieved a net margin of 20.96% and a return on equity of 137.41% during the reported period.

🎯 Full-year 2026 EPS guidance is set between $21.70 and $23.10, aligning closely with analyst forecasts of $22.31.

📉 Argus Capital Group lowered its price target from $400 to $375 while maintaining a 'buy' rating on the stock.

📉 Wall Street Zen downgraded Amgen from 'buy' to 'hold' in a recent research note dated June 27th.

🏦 BMO Capital Markets reaffirmed an 'outperform' rating with a $400 price target issued on July 1st.

📉 SVP Nancy Grygiel sold 1,237 shares worth approximately $400,454 in a transaction completed on May 4th.

📊 Amgen's stock trades at a P/E ratio of 24.94 with a market capitalization of $193.39 billion.

Bullish Signals
  • Amgen reported Q1 EPS of $5.15, significantly beating the consensus estimate of $4.77 by $0.38.
  • Revenue reached $8.62 billion, surpassing analyst estimates of $8.58 billion and growing 5.8% year-over-year.
  • The company achieved a robust net margin of 20.96% and an impressive return on equity of 137.41%.
  • Full-year 2026 EPS guidance of $21.70-$23.10 aligns closely with analyst expectations of $22.31.
  • BMO Capital Markets reaffirmed an 'outperform' rating and set a high price target of $400.
Risk Factors
  • Bank of New York Mellon Corp, a major institutional holder, reduced its stake by 2.9% in the first quarter.
  • Wall Street Zen downgraded Amgen from a 'buy' to a 'hold' rating in late June.
  • Argus Capital Group lowered its price objective from $400 to $375 despite maintaining a buy rating.
  • The stock trades below its 200-day moving average of $350.00 while hovering near the 50-day average.
Full Analysis
Bank of New York Mellon Corp reduced its stake in Amgen Inc. (NASDAQ: AMGN) by 2.9% in the first quarter, selling 113,573 shares to hold a position valued at approximately $1.33 billion. While several smaller institutional investors like Anfield Capital and Dogwood Wealth Management increased their holdings significantly, these positions remain negligible in absolute terms compared to major holders. Hedge funds and other institutions collectively own 76.50% of the company's outstanding stock. Analyst sentiment regarding Amgen remains mixed with a consensus price target of $356.62. Argus Capital Group lowered its price objective from $400 to $375 while maintaining a 'buy' rating, whereas Wall Street Zen downgraded the stock from 'buy' to 'hold'. Other major firms like BMO Capital Markets and Guggenheim maintained their respective 'outperform' and 'neutral' ratings with targets near current market levels. Financially, Amgen reported strong quarterly results for the quarter ended April 30th, posting $5.15 in earnings per share which beat consensus estimates of $4.77. Revenue reached $8.62 billion, a 5.8% year-over-year increase that also surpassed analyst expectations of $8.58 billion. The company achieved a net margin of 20.96% and a return on equity of 137.41%, with shares trading at a P/E ratio of 24.94. The stock currently trades around $358, sitting above its 50-day moving average but slightly below its 200-day average. Management provided full-year 2026 earnings guidance ranging between $21.70 and $23.10 per share, which aligns closely with analyst expectations of $22.31. Insider trading activity saw SVP Nancy Grygiel sell a portion of her holdings, reducing her stake by 15%.